Boston Scientific Corp

BSX remains in a Stage 4 – Decline with persistent lower highs and lower lows under declining EMAs, maintaining a bearish posture across long and medium terms. Short-term coiling between the 9 and 20 EMAs, combined with an oversold context lacking exhaustion, suggests deferring selling into strength near the EMA cluster. Overall, trim positions on rallies into the falling EMA zone to align with the dominant downtrend.

• ↑Q1 2026 revenue $5.203B (+11.6% YoY) and EPS $0.80 (+6% YoY) beat consensus
• ↑Proposed Penumbra acquisition closing in 2026 strengthens interventional oncology
• ↓Full-year organic growth guidance trimmed from 10–12% to 6.5–8% for 2026